Acrux Pharmaceuticals

Acrux Pharmaceuticals is a company listed under the stock ticker ACXP (US).

View the org chart displaying its 11 main executives

Most searched biographies at Acrux Pharmaceuticals

• David Luci, President and Chief Executive Officer
• Jack Dean, Director
• Thomas Harrison, Director

Create your alert
to follow the executive moves at Acrux Pharmaceuticals.

Acrux Pharmaceuticals has 2,290 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Acrux Pharmaceuticals

• Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
• Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
• Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
• Press Releases
• Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
• Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
• Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
• Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
• Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
• Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference
• View more press releases Close

Social media about Acrux Pharmaceuticals

• Acrux Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Acrux Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including David Luci

Call Acrux Pharmaceuticals at +1 917...

View the org chart

Register to receive your alert

Report an error